Dimensional Fund Advisors LP Boosts Position in Corcept Therapeutics Incorporated (CORT)

Dimensional Fund Advisors LP increased its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 41.8% in the third quarter, HoldingsChannel reports. The firm owned 1,204,325 shares of the biotechnology company’s stock after purchasing an additional 355,006 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Corcept Therapeutics were worth $23,242,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of CORT. Victory Capital Management Inc. acquired a new position in Corcept Therapeutics in the third quarter worth about $108,000. BNP Paribas Arbitrage SA grew its stake in Corcept Therapeutics by 2,942.9% in the second quarter. BNP Paribas Arbitrage SA now owns 9,707 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 9,388 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Corcept Therapeutics by 52.6% in the second quarter. PNC Financial Services Group Inc. now owns 9,837 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 3,390 shares in the last quarter. Amalgamated Bank acquired a new position in Corcept Therapeutics in the second quarter worth about $137,000. Finally, Macquarie Group Ltd. acquired a new position in Corcept Therapeutics in the third quarter worth about $137,000. Institutional investors and hedge funds own 64.64% of the company’s stock.

Corcept Therapeutics Incorporated (NASDAQ CORT) opened at $23.98 on Friday. Corcept Therapeutics Incorporated has a 52 week low of $6.70 and a 52 week high of $24.02. The company has a market capitalization of $2,780.00, a P/E ratio of 82.69 and a beta of 1.89.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 EPS for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.02). Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. The company had revenue of $42.70 million during the quarter, compared to analyst estimates of $41.64 million. During the same quarter in the previous year, the firm earned $0.02 earnings per share. The business’s revenue was up 96.8% on a year-over-year basis. research analysts forecast that Corcept Therapeutics Incorporated will post 0.47 EPS for the current fiscal year.

In other Corcept Therapeutics news, insider Robert S. Fishman sold 8,000 shares of Corcept Therapeutics stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $16.72, for a total value of $133,760.00. Following the completion of the transaction, the insider now directly owns 8,000 shares in the company, valued at $133,760. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director G Leonard Baker, Jr. sold 30,000 shares of Corcept Therapeutics stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $17.59, for a total value of $527,700.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,000 shares of company stock valued at $810,820. 19.20% of the stock is currently owned by insiders.

A number of equities analysts recently commented on the company. BidaskClub upgraded Corcept Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Finally, Piper Jaffray Companies set a $30.00 target price on Corcept Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 31st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Corcept Therapeutics currently has an average rating of “Buy” and an average price target of $21.00.

ILLEGAL ACTIVITY NOTICE: “Dimensional Fund Advisors LP Boosts Position in Corcept Therapeutics Incorporated (CORT)” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3148514/dimensional-fund-advisors-lp-boosts-position-in-corcept-therapeutics-incorporated-cort.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.